Sign up USA
Proactive Investors - Run By Investors For Investors

Akebia Therapeutics surges on vadadustat agreement

Vadadustat is an oral, investigational hypoxia-inducible factor (HIF) stabilizer currently in Phase 3 development
Akebia Therapeutics surges on vadadustat agreement
The group struck an exclusive license agreement to sell vadadustat, once approved, to Fresenius Medical Care dialysis clinics

Akebia Therapeutics Inc ( NASDAQ: AKBA) shares shot up Tuesday after it struck an exclusive license agreement with Vifor Pharma Group to sell lead candidate vadadustat, once approved, to Fresenius Medical Care dialysis clinics.

The deal will provide vadadustat to Fresenius Medical Care in the USA when the FDA has approved it.

Vadadustat is an oral, investigational hypoxia-inducible factor (HIF) stabilizer currently in Phase 3 development for the treatment of anemia related to chronic kidney disease.

Shares in Akebia are up over 14% at the time of writing, at $14.75.

Vifor Pharma will also make a $50 million equity investment in Akebia at $14 per share, it said.

Vadadustat could represent a significant advancement in the treatment of renal anemia with the potential to establish a new treatment paradigm and overcome the limitations of current therapies for patients with chronic kidney disease," said Stefan Schulze,  Chief Operating Officer of Vifor Pharma

He added:  "This transaction strengthens the nephrology product portfolio of Vifor Pharma, and is consistent with our ongoing commitment to deliver innovative products that can improve the lives of patients suffering with chronic kidney disease.”

"This agreement provides the opportunity to build greater commercial momentum for vadadustat in the U.S. rapidly upon launch,” said John P. Butler, president and chief executive of Akebia.

"We are pleased that Vifor Pharma has selected vadadustat as its exclusive HIF product for distribution to Fresenius Medical Care, one of the largest dialysis providers. We believe that this commitment provides significant further validation of vadadustat’s potential.”

Giles_55af4ddca6481.jpg


Register here to be notified of future PROAC Company articles
View full PROAC profile View Profile

Proactiveinvestors Timeline

Related Articles

E-mail
October 18 2016
Geographical expansion, product innovation and strategic partnerships continue to be well executed, said house broker finnCap
White board with marketing ideas
March 13 2017
There was a bit of a wobble in the run-up to the Brexit vote and shortly after it, but the group's 'buy, build & grow' strategy is taking shape
learning symbol on a keyboard
January 16 2017
The English language learning specialist is confident it can kick on in the coming year
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use